125 related articles for article (PubMed ID: 18188796)
1. [Intravitreal injection of bevacizumab (Avastin) for retinal angiomatous proliferation].
Amselem L; Díaz-Llopis M; Cervera E; García-Delpech S; Moratal-Peiro B; Palomares P
Arch Soc Esp Oftalmol; 2008 Jan; 83(1):53-6. PubMed ID: 18188796
[TBL] [Abstract][Full Text] [Related]
2. [Anti-VEGF treatment for retinal angiomatous proliferation].
Wolf A; Kook D; Kreutzer T; Gandorfer A; Haritoglou C; Kampik A; Ulbig M
Ophthalmologe; 2008 Sep; 105(9):845-51. PubMed ID: 18607601
[TBL] [Abstract][Full Text] [Related]
3. Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation.
Rouvas AA; Papakostas TD; Ladas ID; Vergados I
Graefes Arch Clin Exp Ophthalmol; 2008 Feb; 246(2):315-8. PubMed ID: 17957379
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation.
Ghazi NG; Knape RM; Kirk TQ; Tiedeman JS; Conway BP
Retina; 2008 May; 28(5):689-95. PubMed ID: 18463511
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration.
Lai TY; Chan WM; Liu DT; Lam DS
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1877-80. PubMed ID: 17901972
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for occult subfoveal neovascularization in age-related macular degeneration.
Jonas JB; Harder B; Spandau UH; Kamppeter BA; Libondi T; Sauder G
Eur J Ophthalmol; 2006; 16(5):774-5. PubMed ID: 17061237
[TBL] [Abstract][Full Text] [Related]
10. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
Engelbert M; Zweifel SA; Freund KB
Retina; 2009; 29(10):1424-31. PubMed ID: 19898180
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
12. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
Ronan SM; Yoganathan P; Chien FY; Corcóstegui IA; Blumenkranz MS; Deramo VA; Elner SG; Fastenberg DA; Johnson MW; López M; Mateo C; Moshfeghi DM; Navarro R; Rosenblatt BJ; Sanislo SR; Saxe SJ; Zacks DN
Retina; 2007 Jun; 27(5):535-40. PubMed ID: 17558313
[TBL] [Abstract][Full Text] [Related]
13. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin).
Nicolò M; Ghiglione D; Calabria G
Eur J Ophthalmol; 2006; 16(5):770-3. PubMed ID: 17061236
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
Pedersen KB; Sjølie AK; Møller F
Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
[TBL] [Abstract][Full Text] [Related]
15. Retinal angiomatous proliferation and intravitreal bevacizumab injection.
Kang JH; Park KA; Chung SE; Kang SW
Korean J Ophthalmol; 2007 Dec; 21(4):213-5. PubMed ID: 18063885
[TBL] [Abstract][Full Text] [Related]
16. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
Chan CK; Meyer CH; Gross JG; Abraham P; Nuthi AS; Kokame GT; Lin SG; Rauser ME; Kaiser PK
Retina; 2007 Jun; 27(5):541-51. PubMed ID: 17558314
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.
Reche-Frutos J; Calvo-Gonzalez C; Pérez-Trigo S; Fernandez-Perez C; Donate-Lopez J; Garcia-Feijoo J
Eur J Ophthalmol; 2011; 21(6):783-8. PubMed ID: 21484755
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation.
Joeres S; Heussen FM; Treziak T; Bopp S; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1597-602. PubMed ID: 17437123
[TBL] [Abstract][Full Text] [Related]
19. Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin.
Mantel I; Ambresin A; Zografos L
Eur J Ophthalmol; 2006; 16(5):705-10. PubMed ID: 17061221
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation.
Costagliola C; Romano MR; dell'Omo R; Cipollone U; Polisena P
Am J Ophthalmol; 2007 Sep; 144(3):449-51. PubMed ID: 17765426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
